Table 2.
Patient characteristics
| Study | N | M/F | Age (year) Mean range |
KPS (%) (Mean) |
KPS ≥ 70% |
Glioma WHO II (n) | Glioma WHO III (n) | Glioma WHO IV (n) | Median OS (months) range | References |
|---|---|---|---|---|---|---|---|---|---|---|
| Bae, 2013 | 300 | 187/113 | 49 17–84 |
87 | 20 | 67 | 213 | [32] | ||
| Brada, 2001 | 138 | 85/53 | 54 24–77 |
100% (KPS > 70%) |
138 | [25] | ||||
| Cao, 2012 | 112 | 73/39 | 70 60–86 |
80 | 0 | 0 | 112 | 7 | [33] | |
| Chen, 2017 | 712 | 400/312 | 55 | 77 | 128 | 507 | [39] | |||
| Diamond, 2017 | 50 | 34/16 | 50 18–77 |
16 | 34 | [26] | ||||
| Ening, 2015 | 233 | 117/116 | 58 | 79% (KPS > 70%) |
0 | 0 | 233 | 9.5 0–72 |
[53] | |
| Iuchi, 2014 | 121 | 74/47 | 58 | 19 | 21 | 81 | [40] | |||
| Jakola, 2012 | 55 | 30/25 | 41 | 91% (KPS ≥ 80%) |
55 | [27] | ||||
| Kerkhof, 2013 | 291 | 169/122 | 60 24–85 |
0 | 0 | 291 | 13 | [41] | ||
| Kim, 2013 | 406 | 244/162 | 51 18–86 |
75% (KPS > 70%) |
0 | 124 | 282 | [42] | ||
| Kocher, 2005 | 81 | 53/28 | 52 15–72 |
83 | 12 | 22 | 47 | [54] | ||
| Koekkoek, 2014 | 178 | 125/53 | 60 | 20%3 m 2%1 w |
0 | 19 | 159 | 12.4 gr III 10.6–14.1 10.6 gr IV 9.2–12.1 |
[23] | |
| Liang, 2016 | 184 | 100/84 | 49 20–69 |
47 e 56 we |
184 | [43] | ||||
| Malström, 2012 | 291 | 173/118 | 70 | 0 | 0 | 291 | 8.3 chemo 6.0 rt 7.5 hypofr rt |
[28] | ||
| Mamo, 2017 | 64 | 40/24 | 54 26–83 |
88% | 64 | [34] | ||||
| Piribauer, 2003 | 103 | 65/38 | > 55 55–83 |
79 | 0 | 0 | 103 | 17.5 py 8.6 pe |
[44] | |
| Posti, 2015 | 142 | 76/66 | 60 | 29 | 31 | 82 | [45] | |||
| Rasmussen, 2017 | 1930 | 1158/772 | 18–79 | 247 | 279 | 1364 | [29] | |||
| Russo, 2017 | 527 | 314/213 | 53 | 139 | 87 | 268 | [38] | |||
| Sagberg, 2013 | 164 | 56 | 73 | 43 | 121 | [46] | ||||
| Saito, 2014 | 76 | 50/26 | 47 py 71 pe |
82% py 70% pe |
0 | 0 | 76 | 15.2 12.9–18.5 21.6 py 15.6 pe |
[35] | |
| Salmaggi, 2005 | 134 | 82/52 | 61 | 85% | 0 | 0 | 134 | [47] | ||
| Sanai, 2012 | 119 | 45 18–81 |
75 | 34 | 23 | 62 | [48] | |||
| Seekatz, 2017 | 54 | 60 24–79 |
54 | [30] | ||||||
| Sizoo, 2010 | 58 | 39/19 | 52 18–81 |
0 | 15 | 41 | 21 gr III 11–86 12 gr IV 0.5–71 |
[37] | ||
| Stupp, 2002 | 64 | 39/25 | 52 24–70 |
64% (KPS > 80%) |
64 | 23 | [31] | |||
| Thrier, 2015 | 57 | 39/18 | 59 | 30 | 0 | 0 | 57 | 12 | [55] | |
| Valko, 2014 | 65 | 44/21 | 57 | 80 | 0 | 0 | 65 | [36] | ||
| Van Breemen, 2009 | 108 | 54/54 | 40 53 |
33 | 75 | > 8 years HGG 19 LGG |
[49] | |||
| Woo, 2014 | 198 | 122/76 | 55 18–88 |
81% | 125 | 73 | 9.0 11.0 gr III 8.0 gr IV |
[50] | ||
| You, 2012 | 508 | 306/202 | 38 16–72 |
88% (KPS ≥ 80%) |
508 | 0 | 0 | 32.9 12–58.3 |
[51] | |
| Yuile, 2006 | 133 | 84/49 | 59 22–86 |
0 | 0 | 133 | 10 0.1–51.8 |
[52] |
Chemo chemotherapy, e with epilepsy, gr III grade III glioma, gr IV grade IV glioma, HGG high grade glioma, hypofr hypofractioned, LGG low grade glioma, OS overal survival rate, pe patients of 65 years or older, py patients younger than 65 years, rt radiotherapy, we without epilepsy, 3 m 3 months before death, 1 w 1 week before death